Switch to:
More From Other Websites
Appendix 3B New Nov 22 2016
Change in Director's Interest New Nov 07 2016
NOVOGEN LTD Financials Nov 03 2016
Change in Director's Interest New Nov 03 2016
Change in Director's Interest New Nov 01 2016
Conversion of convertible notes and issue of Options New Nov 01 2016
In-licensing of GDC-0084 – Investor Presentation New Nov 01 2016
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in... Oct 30 2016
Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma Oct 30 2016
Appendix 3B and Cleansing Notice New Oct 30 2016
In-licensing of GDC-0084 New Oct 30 2016
Novogen Licenses Phase II-ready Molecule from Genentech for Development in Glioblastoma for $5M... Oct 30 2016
Novogen Acquires Privately-held Glioblast for AU$2.1M in Cash, Stock, Plus Milestones Oct 30 2016
In-licensing of GDC-0084 New Oct 30 2016
Accompanying Investor Presentation New Oct 30 2016
Acquisition of Glioblast New Oct 30 2016
SEC Form 20F New Oct 28 2016
Appendix 4G and Corporate Governance Statement New Oct 25 2016
Issue of unlisted options under ESOP New Oct 20 2016
Annual Report for the year ended 30 June 2016 New Oct 20 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK